Forum Topic News
  • Conversation: Applied BioMath, LLC Announces Collaboration with Obsidian Therapeutics for Semi-Mechanistic Quantitative Modeling of a Novel Therapeutic Platform

    • November 20, 2018 9:58 AM GMT
    • Applied BioMath, LLC Announces Collaboration with Obsidian Therapeutics for Semi-Mechanistic Quantitative Modeling of a Novel Th...

      Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug research and development, today announced a collaboration with Obsidian Therapeutics to provide semi-mechanistic models and analysis services. Applied BioMath will create semi-mechanistic models, using in vitro and in vivo preclinical data, to aid in dose prediction and knowledge gap identification for Obsidian's promising therapeutic strategy. "Our Destablizing Domain platform is exceedingly powerful but also pharmacologically complex," said Steve Shamah, Senior Vice President of Research, of Obsidian Therapeutics. "We chose to work with Applied BioMath because of their proven track record of delivering impactful results in a very short timeframe."
      Obsidian Therapeutics, founded by Atlas Venture in 2015, is developing next-generation cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. Applied BioMath will leverage their proprietary algorithms and software to develop semi-mechanistic models for Obsidian using rigorous fit-for-purpose model development processes and optimization techniques to estimate model parameters and variability.
      Read more: https://www.prnewswire.com/news-releases/applied-biomath-llc-announces-collaboration-with-obsidian-therapeutics-for-semi-mechanistic-quantitative-modeling-of-a-novel-therapeutic-platform-300753053.html

Add Reputation

Do you want to add reputation for this member by this post?

or cancel
‚Äč